Insights on growing and managing portfolios
Perspectives and news from Pharmagro across portfolio strategy, pharma, biotech and CDMO.
Case Study : Choosing the Right Manufacturing Partner for a Phase 3 Biologic
How we navigated compounding process changes, non-comparable proposals, and hidden CDMO risks.
Case Study: Technical Due Diligence on a Biologic
In just four weeks we provided a strong analysis of CMC elements, embedded in financial, legal and operational issues.
P2MT Software Update
We have made our Pharmagro Portfolio ManagementTool P2MT easier to use! In the Evaluation Section we have added templates. Use these to get started quickly on your evaluations.
Asia’s Growing Strength in CDMOs
Listen to the HealthAlpha podcast. Host Sushaant Bakhru talks to Pharmagro’s Nick Wigdahl
From Lab To Product
CRO and CDMO Business Dynamics 2026-30: A.I., Automation & Performance
Business Development
Which is harder – selling into a Big Pharma company or climbing the North Face of the Eiger? Many small CDMOs might prefer to climb the Eiger, long considered one of the hardest challenges in mountaineering.
CPHI – Pharmagro Launches P2MT
Pharmagro chose the CPHI 2025 Messe to launch its new Portfolio Management Tool. This version is aimed at CDMOs Contract Development and Manufacturing Organisations. The key features are:
Devices – Beware Extended Duration, Heightened Risk
Patient Centricity has become a watchword in the industry.
Pharmagro Portfolio Management Tool
Once a CDMO reaches around 50 molecules it is important to have a portfolio management tool in place.
Risk Management
Risk mitigation is about practising and getting better at what you do.
Bring us the portfolio decision you need to make.
See how Pharmagro could help your team structure the uncertainty, explore alternative scenarios and move toward a clearer decision.
